InvestSMART

Proteomics International Laboratories Ltd (ASX:PIQ)

ALERT: Price-sensitive ASX Announcement for PIQ
Current share price for PIQ : $0.190 -0.165 (-46.48%)+
Announcement
Release
25 Feb 2026 8:43AM
Price at Release
$0.355
Full Release
download
Summary
Proteomics International Laboratories Ltd, a leading company in precision diagnostics and bioanalytical services, reported its interim financial results for the half-year ended 31 December 2025. The company experienced a 10% decrease in total revenue compared to the previous period, amounting to $868,749. The loss after tax attributable to its members was $6,026,951, marking a 34% increase from the previous year. Key developments included the controlled market launches of diagnostic products Promarker®D and Promarker®Eso in Australia, with Promarker®D also securing reimbursement pricing in the US, effective from January 2026. The company also strengthened its global intellectual property portfolio, including securing additional US patent protection for Promarker®Eso. Looking forward, the company aims to expand its market presence and commercial scale, particularly in the US, while focusing on clinical validation and regulatory readiness to drive sustainable value creation.
Key Points
  • Revenues decreased by 10% to $868,749 compared to the previous period.
  • Loss after tax for members increased by 34% to $6,026,951.
  • Controlled market launches of Promarker®D and Promarker®Eso in Australia.
  • US reimbursement pricing established for Promarker®D, effective January 2026.
  • Strengthened global intellectual property with a new US patent for Promarker®Eso.
  • Focus on expanding market presence and commercial scale, particularly in the US.
  • Strategic priorities include growing clinician adoption and innovating diagnostic solutions.
  • Company aims to convert clinical validation into commercial expansion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.